- Home
- CHGG vs ONCY Comparison
CHGG vs ONCY Comparison
Compare CHGG & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHGG | ONCY |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.4M | 98.7M |
| IPO Year | 2013 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CHGG | ONCY |
|---|---|---|
| Price | $1.08 | $0.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $376,908,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.52 | $0.77 |
| 52 Week High | $1.87 | $1.51 |
Technical Indicators
Market Signals| Indicator | CHGG | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 49.82 |
| Support Level | $0.88 | $0.90 |
| Resistance Level | $1.20 | $1.06 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 46.70 | 53.40 |
Price Performance
Historical ComparisonAbout CHGG Chegg Inc.
Chegg Inc is an American educational services company. The Chegg platform provides products and services to support learners with their academic course materials, as well as their career and personal skills development. The company's service and product offerings fall into two categories: Chegg Skilling; and Academic Services, which derives maximum revenue. Geographically, it derives in United States and International.
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.